Viking Therapeutics (NASDAQ:VKTX – Get Free Report) posted its earnings results on Wednesday. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.06, Briefing.com reports. During the same period last year, the firm posted ($0.19) EPS.
Viking Therapeutics Stock Up 2.0 %
NASDAQ VKTX traded up $1.30 during trading hours on Friday, hitting $65.98. 9,296,767 shares of the company were exchanged, compared to its average volume of 4,218,861. The company has a 50 day moving average of $55.72 and a two-hundred day moving average of $56.21. Viking Therapeutics has a 52-week low of $8.28 and a 52-week high of $99.41. The firm has a market cap of $7.31 billion, a price-to-earnings ratio of -70.95 and a beta of 1.03.
Insiders Place Their Bets
In other news, CFO Greg Zante sold 66,756 shares of the company’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $74.69, for a total transaction of $4,986,005.64. Following the completion of the transaction, the chief financial officer now directly owns 174,854 shares of the company’s stock, valued at approximately $13,059,845.26. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CFO Greg Zante sold 66,756 shares of the company’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $74.69, for a total transaction of $4,986,005.64. Following the completion of the transaction, the chief financial officer now directly owns 174,854 shares of the company’s stock, valued at approximately $13,059,845.26. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Marianna Mancini sold 281,425 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $78.66, for a total value of $22,136,890.50. Following the transaction, the chief operating officer now directly owns 348,508 shares of the company’s stock, valued at $27,413,639.28. The disclosure for this sale can be found here. 4.70% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
View Our Latest Analysis on Viking Therapeutics
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
See Also
- Five stocks we like better than Viking Therapeutics
- What Is WallStreetBets and What Stocks Are They Targeting?
- Why Call Options Volume for These 2 Stocks Spiked Together
- Russell 2000 Index, How Investors Use it For Profitable Trading
- MarketBeat Week in Review – 7/22 – 7/26
- 3 REITs to Buy and Hold for the Long Term
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.